Pantarhei Bioscience and Pantarhei Oncology are Dutch bio-pharmaceutical companies that develop unique new treatment concepts in the areas of Women’s Health and Reproductive Endocrine Oncology. Founded in 2000 by the former R&D executive of Organon Herjan Coelingh Bennink, it has since then filed more than 220 patents.
The Pantarhei pipeline focus on phase I and II clinical research for innovative, safe and effective oncological treatments for cancers sensitive to endocrine treatment, as well as reproductive hormone related gynaecological treatments and applications. In our approach we build upon the effective applications of existing biological compounds, with a safety track record. Based upon thorough scientific knowledge and divergent thinking and our clinical and scientific endocrine healthcare background, we develop new treatments in the area of Women’s Health, especially new methods of hormonal contraception, menopausal hormone treatment and infertility, and in Reproductive Endocrine Oncology with special emphasis on breast cancer, prostate cancer, ovarian cancer and lung cancer. We always have a dual goal: effective and safe new treatments and improvement of quality of life and wellbeing.
The Pantarhei companies develop the new drugs up to phase II efficacy and safety. We create intellectual property (IP) for the new treatment concepts, provide in-house project management and select the best in class partners in the world for the outsourcing of our research and development activities. After generating favourable and safe human proof-of-concept data, projects are sold or licensed-out to a (pharmaceutical) partner for final development (phase III), regulatory approval and commercialisation. Over the years, Pantarhei has sold and licensed a series of unique Women’s Health treatment concepts to Serono (now Merck), Schering (now Bayer), HRA Pharma SA, Mithra Pharmaceuticals and Gedeon Richter. In the area of Reproductive Endocrine Oncology, Pantarhei has performed promising clinical efficacy studies in patients with advanced breast and prostate cancer.